To empower individuals with the freedom to gain greater control over health

tumor diagnosis

HOME    medical application    tumor diagnosis

World Cancer Report, the number of cancer cases in China in 2012 was 3.065 million, accounting for about 1/5 of the global incidence, and the number of cancer deaths was 2.205 million, accounting for about 1/4 of the global cancer deaths. The incidence of cancer in China is close to the world level, but the mortality rate is higher than the world level. In cancer treatment, traditional chemotherapy and radiotherapy, due to the lack of specificity, often bring greater toxic side effects to patients while achieving curative effects. Therefore, the selection of specific molecular targets for treatment has attracted increasing attention. While achieving obvious curative effects, it can avoid damage to normal cells.
EGFR is currently recognized by researchers at home and abroad as a tumor targeted therapy molecule. EGFR mutation is a strong predictor of TKI sensitivity in cancer patients. Various studies have also shown that EGFR mutations or amplification exist in a variety of tumor cells. Therefore, to clarify the EGFR mutation status of NSCLC tissue has important guiding significance for clinical use and efficacy prediction of targeted drugs. However, clinical studies have shown that patients with metastatic colorectal cancer with KRAS gene mutation are resistant to EGFR targeted therapeutic drugs such as cetuximab and panitumab. Therefore, health departments in various countries require colorectal cancer patients to undergo KRAS gene mutation detection before receiving these EGFR-targeted drugs. According to the test results, whether to use EGFR targeted drugs as clinical treatment measures. KRAS gene mutation detection can improve the pertinence of tumor clinical treatment, effectively reduce the treatment cost and save valuable treatment time.
The EGFR gene mutation detection kit (PCR-fluorescent probe method) and KRAS gene mutation detection kit (PCR-fluorescent probe method) under Hesi Bio can be used to qualitatively detect the corresponding mutations of EGFR and KRAS genes, and evaluate the effect of drug treatment. Guide the clinic to formulate appropriate treatment plans.

EGFR 29 Mutation Detection Kit (PCR-Fluorescent Probe Method)
KRAS 7 Mutation Detection Kit (PCR-Fluorescent Probe Method)

Created on:2020-06-03 19:33